CD19 and lymphoma: Firstly, in a Pilot/Phase I study investigating the efficacy of CD19-CAR T cell therapy in patients with CD19-positive leukemia or lymphoma, TET2 dysfunction led to altered T cell differentiation, with a central memory phenotype at the peak of expansion in a patient with CLL [36].